P409: Non-invasive predictors of maintaining remission in patients with moderately to severely active Ulcerative Colitis treated with tofacitinib who dose-reduced from tofacitinib 10 mg twice daily to 5 mg twice daily: 6-month data from the double-blind, randomised RIVETING studyECCO'21 VirtualYear: 2021
Authors: D’Haens, G.R.(1);Dubinsky, M.C.(2);Regueiro, M.(3);Santana, G.O.(4);Torres, J.(5);Kulisek, N.(6);Gardiner, S.(7);Mundayat, R.(7);Paulissen, J.(7);Lawendy, N.(6);Su, C.(6);Modesto, I.(7);Sandborn, W.J.(8);
(1)Department of Gastroenterology, Amsterdam University Medical Centres, Amsterdam, The Netherlands;(2)Icahn School of Medicine at Mount Sinai, New York, New York, United States;(3)Department of Gastroenterology- Hepatology and Nutrition, Cleveland Clinic, Cleveland- Ohio, United States;(4)University of the State of Bahia, Salvador, Bahia, Brazil;(5)Surgical Department- Gastroenterology Division, Hospital Beatriz Ângelo- Loures, and Faculdade de Medicina- Universidade de Lisboa- Lisbon, Portugal;(6)Pfizer Inc, Collegeville, Pennsylvania, United States;(7)Pfizer Inc, New York, New York, United States;(8)Division of Gastroenterology, University of California, San Diego- La Jolla- California, United States
P410: Which patients with established Crohn's disease benefit most from the use of the Patency capsule test prior to small bowel capsule endoscopy?ECCO'21 VirtualYear: 2021
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Rodríguez Gutiérrez, C.(2);Vicuña Arregui, M.(2);Elizalde Apesteguía, I.(2);Aznárez Barrio, M.R.(2);Juanmartiñena Fernández, J.F.(2);Nantes Castillejo, Ó.(2);Fernández-Urién, I.(2);
(1)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain
P412: Effectiveness of ustekinumab in fistulising perianal Crohn´s disease refractory or intolerant to anti-TNFECCO'21 VirtualYear: 2021
Authors: Carpio, D.(1);Calviño-Suarez , C.(2);Martínez-Cadilla , J.(3);Molina , G.(4);Vázquez-Rey , M.T.(5);Martí , E.(6);Fernández-Salgado , E.(1);Barreiro-de Acosta , M.(2);Hernández , V.(3);Echarri , A.(4);Diz-Lois , M.T.(5);Baz , A.(6);
(1)Complejo Hospitalario Universitario de Pontevedra, Gastroenterology, Pontevedra, Spain;(2)Complexo Hospitalario Universitario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(3)Complexo Hospitalario Universitario de Vigo, Gastroenterology, Vigo, Spain;(4)Complexo Hospitalario Universitario de Ferrol, Gastrenterology, Ferrol, Spain;(5)Complexo Hospitalario Universitario de A Coruña, Gastroenterology, A Coruña, Spain;(6)Hospital Universitario Lucus Augusti, Gastroenterology, Lugo, Spain; EIGA (Grupo Galego de Enfermedad Inflamatoria Intestinal)
P413: Characteristics of the stricture, not the ongoing treatment, influence the outcome of endoscopic dilatation in recurrent Crohn`s disease.ECCO'21 VirtualYear: 2021
Authors: Ladrón Abia, P.(1); Alonso, N.(2);Beltrán, B.(1);Minguez, A.(1);Sáez-González, E.(1);Pons-Beltrán, V.(2);Nos, P.(1);Iborra, M.(1);
(1)Hospital Universitari i Politècnic La Fe, Gastroenterology Unit- Digestive Diseases Department, Valencia, Spain;(2)Hospital Universitari i Politècnic La Fe, Gastrointestinal Endoscopy Unit- Digestive Diseases Department, Valencia, Spain
P414: Obesity is associated with a higher risk of immunogenicity to adalimumab, but not to infliximab in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Mahmoud, R.(1);Schultheiss, J.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);Mahmmod, N.(2);van Boeckel, P.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1);
(1)University Medical Centre Utrecht, Division of Internal Medicine and Dermatology- Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)St. Antonius Hospital, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(3)Meander Medical Centre, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands
P415: Paradoxical onset of Takayasu’s arteritis in patients with inflammatory bowel disease treated with anti-tumour necrosis factor-α agentsECCO'21 VirtualYear: 2021
Authors: Matsune, Y.(1);Kouyama, J.(1);Tsuru, Y.(1);Shimizu, K.(1);Asami, S.(1);Matsuyama, S.(1);Katsuki, S.(1);Ishihara, H.(1);Onizawa, R.(1);Shonai, S.(1);Tatsuno, M.(1);Nishikawa, Y.(1);Takeuchi, K.(1);Watanabe, M.(1);Nakamori, Y.(1);Hirayama, A.(1);Toyoda, J.(1);Ikeda, A.(1);Madarame, A.(1);Nishio, M.(1);Ogashiwa, T.(1);Matsubayashi, M.(1);Fujii, A.(1);Kimura, H.(1);Kunisaki, R.(1);
(1)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan
P416: Use of DXA in children with Inflammatory Bowel Disease – a large single centre studyECCO'21 VirtualYear: 2021
Authors: Jois, A.(1);Perera, S.(2);Simm, P.(3);Alex, G.(1);
(1)The Royal Children's Hospital, Gastroenterology and Clinical Nutrition, Melbourne, Australia;(2)The Royal Children's Hospital, General Medicine, Melbourne, Australia;(3)The Royal Children's Hospital, Endocrinology and Diabetes, Melbourne, Australia
P418: Does capsule endoscopy impact clinical management in established Crohn’s Disease?ECCO'21 VirtualYear: 2021
Authors: Elosua Gonzalez, A.(1);Rullan Iriarte, M.(1);Rubio Iturria, S.(2);Oquiñena Legaz, S.(2);Rodríguez Gutiérrez, C.(2);Macías Mendizábal, E.(2);Borda Martín, A.(2);Fernández-Urién Sainz, I.(2);Nantes Castillejo, Ó.(2);
(1)Hospital García Orcoyen, Gastroenterology, Estella, Spain;(2)Complejo Hospitalario de Navarra, Gastroenterology, Pamplona, Spain
P419: Psychological acceptability of surgery in patients with ulcerative colitis after total colectomyECCO'21 VirtualYear: 2021
Authors: Itabashi, M.(1);Hirano, Y.(2,3);Saito, T.(4,5);Inoue, M.(6);Uchida, K.(6);Arai, K.(3);Minakuchi, E.(2);Ishihara, H.(2);Onizawa, R.(2);Hirayama, A.(2);Araki, K.(2);Kimura, H.(2);Kunisaki, R.(2);
(1)Tokyo Women's Medical University, Department of Surgery- Institute of Gastroenterology, Tokyo, Japan;(2)Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan;(3)National Centre for Child Health and Development, Division of Gastroenterology, Tokyo, Japan;(4)Chiba University- Graduate School of Medicine, Department of Pediatric Surgery, Chiba, Japan;(5)Chiba Children's Hospital, Division of Pediatric Surgery, Chiba, Japan;(6)Mie University Graduate School of Medicine, Department of Gastrointestinal and Pediatric Surgery, Mie, Japan
P420: Comparative efficacy and safety of oral ferric maltol in Inflammatory Bowel Disease patients with mild-to-moderate vs. more severe iron deficiency anaemiaECCO'21 VirtualYear: 2021
Authors: Akriche, F.(1);Jacob, I.(2);Schmidt, C.(3);Howaldt, S.(4);
(1)Norgine, Medical, Uxbridge, United Kingdom;(2)Health Economics and Outcomes Research Ltd, Health Economics, Cardiff, United Kingdom;(3)Medical Clinic II- Fulda Hospital, Campus Fulda of Marburg University Hospital, Fulda, Germany;(4)HaFCED e.K., Hamburg Institute of IBD Research, Hamburg, Germany
P421: Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn’s disease – a real-world two-center cohort studyECCO'21 VirtualYear: 2021
Authors: Attauabi, M.(1,2,3);Vind, I.(1,3);Pedersen, G.(1,3);Bendtsen, F.(3);Benedict Seidelin, J.(2);Burisch, J.(1,3);
(1)Copenhagen University Hospital, Gastrounit- Medical Section, Hvidovre, Denmark;(2)Herlev Hospital- University of Copenhagen, Department of Gastroenterology and Hepatology, Herlev, Denmark;(3)University of Copenhagen- Hvidovre Hospital, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults, Hvidovre, Denmark
P423: Treatment escalation and associated cost in German Ulcerative Colitis patients treated with advanced therapiesECCO'21 VirtualYear: 2021
Authors: Picker, N.(1);Patel, H.(2);Wilke, T.(3);Rosin, L.(4);Bokemeyer, B.(5);
(1)Ingress Health, HWM GmbH, Wismar, Germany;(2)Galapagos, Nv, Mechelen, Belgium;(3)IPAM, e.V., Wismar, Germany;(4)Galapagos, Biopharma Deutschland GmbH, München, Germany;(5)Interdisziplinäres Crohn Colitis Center Minden und Medizinische Klinik I- Universitätsklinik Schleswig-Holstein- Campus Kiel, Gastroenterologische Praxis Minden, Minden, Germany
P424: Treatment persistence of first-line anti-TNF therapy in patients with inflammatory bowel diseases: results from a real-world study over 20 yearsECCO'21 VirtualYear: 2021
Authors: Blesl, A.(1);Binder, L.(1);Högenauer, C.(1);Wenzl, H.(1);Borenich, A.(2);Pregartner, G.(2);Berghold, A.(2);Mestel, S.(1);Kump, P.(1);Baumann-Durchschein, F.(1);Petritsch, W.(1);
(1)Medical University of Graz, Division of Gastroenterology und Hepatology, Graz, Austria;(2)Medical University of Graz, Institute for Medical Informatics- Statistics and Documentation, Graz, Austria
P425: Real-world evidence on effectiveness and safety of vedolizumab therapy for inflammatory bowel disease in Taiwan: Results from the TSIBD registry (VIOLET Study)ECCO'21 VirtualYear: 2021
Authors: Wei , S.C.(1);Lin , W.C.(2);Chang , C.H.(3);Tu , C.H.(1);Feng , I.C.(4);Shieh , M.J.(5);Chung , C.S.(6);Yen , H.H.(7);Chou , J.W.(8);Tai , W.C.(9);Wong , J.M.(1);Liu , Y.H.(10);Huang , T.Y.(11);Chuang , C.H.(12);Tsai , T.J.(13);Chiang , F.F.(14);Lu , C.Y.(15);Hsu , W.H.(15);Yu , F.J.(15);Chao , T.H.(14);Wu , D.C.(15);Ho , A.S.(16);Lin , H.H.(17);Feng , C.L.(18);Wu , K.L.(9);Wong , M.W.(19);Tung , C.C.(20);Lin , C.C.(17);Chen , C.C.(3);Hu , H.M.(21);Lu , L.S.(22);Wang , H.S.(23);Wu , I.C.(15);Kuo , H.Y.(24,25);Wu , J.F.(26);Shih , H.Y.(15);Ni , Y.H.(27);Tang , S.L.(28);Chang , H.C.(28);Chen , P.H.(28);
(1)National Taiwan University Hospital- National Taiwan University College of Medicine, Department of Internal Medicine, Taipei, Taiwan;(2)Mackay Memorial Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Taipei, Taiwan;(3)Taichung Veterans General Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Taichung, Taiwan;(4)Chi Mei Medical Center, Division of Gastroenterology and Hepatology, Tainan, Taiwan;(5)National Taiwan University Hospital, Department of Oncology, Taipei, Taiwan;(6)Far Eastern Memorial Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, New Taipei city, Taiwan;(7)Changhua Christian Hospital, Division of Gastroenterology- Department of Internal Medicine, Changhua, Taiwan;(8)China Medical University Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Taichung, Taiwan;(9)Kaohsiung Chang Gung Memorial Hospital, Division of Hepatogastroenterology- Department of Internal Medicine, Kaohsiung, Taiwan;(10)Shin Kong Wu Ho-Su Memorial Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Taipei, Taiwan;(11)Tri-Service General Hospital- National Defense Medical Center, Division of Gastroenterology- Department of Internal Medicine, Taipei, Taiwan;(12)National Cheng Kung University, Department of Internal Medicine- Medical College and Hospital, Tainan, Taiwan;(13)Kaohsiung Veterans General Hospital, Division of Gastroenterology and Hepatology- Department of Medicine, Kaohsiung, Taiwan;(14)Taichung Veterans General Hospital, Division of Colon and Rectal Surgery- Department of Surgery- Chiayi and Wangiao Branch, Taichung, Taiwan;(15)Kaohsiung Medical University Hospital- Kaohsiung Medical University, Division of Gastroenterology- Department of Internal Medicine, Kaohsiung, Taiwan;(16)Cheng Hsin General Hospital, Division of Gastroenterology- Department of Internal Medicine, Taipei, Taiwan;(17)Taipei Veterans General Hospital, Division of Colon & Rectal Surgery- Department of Surgery, Taipei, Taiwan;(18)China Medical University Hsinchu Hospital, Division of Gastroenterology and Hepatology, Hsinchu, Taiwan;(19)Hualien Tzu Chi Hospital- Buddhist Tzu Chi Medical Foundation and Tzu Chi University, Department of Medicine, Hualien, Taiwan;(20)National Taiwan University Hospital, Department of Integrated Diagnostics & Therapeutics, Taipei, Taiwan;(21)Kaohsiung Municipal Ta-Tung Hospital, Department of Internal Medicine, Kaohsiung, Taiwan;(22)Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Division of Hepato-Gastroenterology- Department of Internal Medicine, Kaohsiung, Taiwan;(23)Taipei Veterans General Hospital- National Yang Ming Chiao Tung University, Division of Colorectal Surgery- Department of Surgery, Taipei, Taiwan;(24)National Cheng Kung University Hospital- College of Medicine- National Cheng Kung University, Department of Internal Medicine, Tainan, Taiwan;(25)National Cheng Kung University, Institute of Clinical Medicine- College of Medicine, Tainan, Taiwan;(26)National Taiwan University Hospital, Department of Pediatrics, Taipei, Taiwan;(27)National Taiwan University, College of Medicine, Taipei, Taiwan;(28)Takeda Pharmaceuticals Taiwan- Ltd., Medical Affairs, Taipei, Taiwan
P426: Health-Related Quality of Life and Work Productivity in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR studyECCO'21 VirtualYear: 2021
Authors: Correa, G.J.(1);Yantorno, M.(1);Olivera Sendra, P.(2,3);Lasa, J.S.(2,4);Lubrano, P.(3);Balderramo, D.C.(5,6);Zubiaurre, I.(4);Ruffinengo, O.(7);Brion, L.(8);Leonardi, D.B.(8);El-Hakeh, J.(8);Guimaraens, P.N.(8);Sambuelli, A.(9);
(1)Hospital Interzonal General de Agudos General José de San Martin, Gastroenterology Department, La Plata- Buenos Aires, Argentina;(2)Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno CEMIC, Gastroenterology Section- Department of Internal Medicine, Buenos Aires, Argentina;(3)Sanatorio Mater Dei, Gastroenterology Department, Buenos Aires, Argentina;(4)Hospital Británico de Buenos Aires, Gastroenterology Department, Buenos Aires, Argentina;(5)Hospital Privado Centro Médico de Córdoba, Gastroenterology Department, Córdoba, Argentina;(6)Instituto Universitario de Ciencias Biomédicas de Córdoba, Department of Internal Medicine, Córdoba, Argentina;(7)Hospital Provincial del Centenario, Gastroenterology and Hepatology Service, Rosario- Santa Fé, Argentina;(8)Takeda Pharma S.A., Medical Affairs, Buenos Aires, Argentina;(9)Hospital de Gastroenterología Dr. Bonorino Udaondo, IBD Section, Buenos Aires, Argentina
P427: Efficacy and safety of vedolizumab and adalimumab in Asian adults with moderately to severely active ulcerative colitis: Post-hoc analysis of the VARSITY trialECCO'21 VirtualYear: 2021
Authors: Kim, J.S.(1);Leung, W.K.(2);Wu, D.C.(3);Lindner, D.(4);Fadeeva, O.(5);Demuth, D.(5);
(1)Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, Korea- Republic Of;(2)University of Hong Kong, Li Ka Shing Faculty of Medicine, Hong Kong, China;(3)Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan- Province Of China;(4)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Zurich, Switzerland;(5)Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals International AG, Singapore, Singapore
P428: Early and Late Fecal Calprotectin Remission - Analysis of a proactive Therapeutic Drug Monitoring Treatment ProtocolECCO'21 VirtualYear: 2021
Authors: Pedro, J.(1);Rodrigues, I.(1);Damião, F.(1);Fernandes, S.(1);Gonçalves, A.R.(1);Bernardo, S.(1);Baldaia, C.(1);Valente, A.(1);Moura Santos, P.(1);Correia, L.(1);Tato Marinho, R.(1);
(1)Centro Hospitalar Lisboa Norte, Gastrenterology, Lisboa, Portugal
